Connect with us

Technology

iRobot Reports First Quarter 2025 Financial Results

Published

on

Global New Product Rollout Continues with High-Impact Launch Events
Company Continues to Execute “iRobot Elevate” Turnaround Strategy

BEDFORD, Mass., May 6, 2025 /PRNewswire/ — iRobot Corp. (NASDAQ: IRBT), a leader in consumer robots, today announced its financial results for the first quarter ended March 29, 2025.

“We continued to make meaningful progress on our iRobot Elevate turnaround strategy in the first quarter and initiated the largest new product launch in iRobot’s history,” said Gary Cohen, iRobot CEO. “We are encouraged by the positive reactions from distributors, retailers and consumers, and expect to see an uptick in sales later in the year as availability of our suite of new, technologically innovative Roomba® vacuums and 2-in-1 vacuums and mops expands. As our Board of Directors continues its review of strategic alternatives for our business, we remain focused on executing our proven strategy and delivering the products our customers have come to know and love.”

The Company has achieved a significant reduction in operating expenses and production costs by transforming its R&D and supply chain model to better leverage the Company’s design capabilities and contract manufacturing partnerships. This reinvention of the way iRobot operates has allowed for a greater focus on innovation and improvements to product features, quality, and software. With respect to the current tariff conditions, the majority of the Company’s U.S. imports come from Vietnam and are currently subject to a 10% tariff rate.

“Our first quarter performance reflects what has been a major transitional period for iRobot as we worked to clear our sales channels of legacy product inventory. As we continue to navigate a dynamic macro environment, we expect our new products and lower overall cost structure to drive improved profitability over the long term. We expect to see solid sales traction later this year to support year-over-year revenue growth in 2025, and we remain on track to deliver gross-margin expansion and improved cash flow from operations this year,” concluded Cohen.

Marketing Highlights

In late March and early April 2025, iRobot announced the availability in North America and select European markets its suite of technologically innovative Roomba® vacuums and 2-in-1 vacuums and mops. Media coverage in North America and Europe was impressive with more than 200 pieces of media coverage in some of the world’s most influential tech/consumer outlets, reaching a potential audience (total UVPM/Circulation/Reach) of more than 2.5 billion.On April 16, 2025, iRobot introduced its new product lineup in Japan, engaging with more than 100 media outlets and influencers, resulting in more than 600 pieces of media coverage in one week.On April 23, 2025, iRobot announced the availability of the Roomba® Max 705 Vac Robot + AutoEmpty™ Dock in North America and select European markets.iRobot has continued to receive positive media coverage and product reviews around the world, including in Tom’s Guide US, Engadget US, Vacuum Wars US, The Independent UK, La Voz de Galicia Spain, Les Numeriques France, Fuji News Network and All the Things.

First Quarter 2025 Financial Results (in millions, except per share amounts and percentages)

Q1 2025

Q1 2024

Revenue

$101.6

$150.0

GAAP Gross Margin

20.0 %

24.1 %

Non-GAAP Gross Margin

22.0 %

24.6 %

GAAP Operating Expenses

$66.1

$24.2

Non-GAAP Operating Expenses

$53.8

$76.9

GAAP Operating (Loss) Income*

($45.8)

$11.9

Non-GAAP Operating Loss

($31.5)

($40.0)

GAAP Net (Loss) Income*

($87.3)

$8.6

Non-GAAP Net Loss

($60.0)

($43.0)

GAAP Net (Loss) Income Per Share*

($2.84)

$0.30

Non-GAAP Net Loss Per Share

($1.95)

($1.53)

*Q1 2024 GAAP operating income, GAAP net income and GAAP net income per share included the one-time net termination fee of $75 million received as a result of the termination of the Amazon Merger Agreement.

 

Additional Financial Highlights 

As of March 29, 2025, the Company’s cash and cash equivalents including restricted cash totaled $112.3 million, compared with $138.0 million at the end of the fourth quarter of 2024. During the third quarter of 2024, the Company elected to draw down $40 million from the restricted cash that is set aside for future repayment of its term loan, subject to limited ability of the Company to utilize such amount at the discretion of the lenders for the purchase of inventory. The Company repaid that amount to restricted cash during the first quarter of 2025.As of March 29, 2025, the Company reduced inventory to $69.0 million, compared with $76.0 million at the end of the fourth quarter of 2024.In the first quarter of 2025, revenue decreased 39.9% in the U.S., 26.9% in EMEA, and 20.8% in Japan, respectively, over the prior-year period. Excluding the unfavorable foreign currency impact, Japan revenue decreased 10% and EMEA revenue decreased 24% over the prior-year period. Q1 2025 revenue was impacted by additional promotional spending to stimulate sell-through of legacy products ahead of the Company’s 2025 new product launch, along with ongoing competitive challenges that the Company is addressing with its new product launches.Revenue from mid-tier robots (with an MSRP between $300 and $499) and premium robots (with an MSRP of $500 or more) represented 76% of total robot sales in the first quarter of 2025, compared with 81% in the same period last year.

Ongoing Strategic Review

As previously announced, the Company’s Board of Directors is conducting a review of strategic alternatives, including, but not limited to, exploring a potential sale or strategic transaction, and refinancing the Company’s debt. This review process is ongoing. 

The Board has not set a timetable for the conclusion of this review, and there can be no assurance that the exploration of strategic alternatives will result in any transactions or outcomes. The Company does not intend to disclose developments relating to this process until it determines that further disclosure is appropriate or necessary.

The Company remains actively engaged in ongoing collaborative and constructive discussions with its primary lender while the Board continues its strategic review process. On April 30, 2025, the Company further amended its existing term loan to extend the covenant waiver under the term loan to June 6, 2025. 

In light of the ongoing strategic review, the Company will not be hosting a first quarter 2025 results earnings conference call and webcast, and will not be providing a 2025 outlook at this time.

About iRobot Corp.

iRobot is a global consumer robot company that designs and builds thoughtful robots and intelligent home innovations that make life better. iRobot introduced the first Roomba robot vacuum in 2002. Today, iRobot is a global enterprise that has sold more than 50 million robots worldwide. iRobot’s product portfolio features technologies and advanced concepts in cleaning, mapping and navigation. Working from this portfolio, iRobot engineers are building robots and smart home devices to help consumers make their homes easier to maintain and healthier places to live. For more information about iRobot, please visit www.irobot.com

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which relate to, among other things: the Company’s expectations regarding the financial profile and impact of newly launched products in 2025; expectations regarding improved profitability; expectations regarding 2025 product sales and related revenue growth, achievement of gross margin expansion and improved cash flow from operations; the Board’s review of strategic alternatives for the business; and the Company’s business plans and strategies and the anticipated impact thereof. These forward-looking statements are based on the Company’s current expectations, estimates and projections about its business and industry, all of which are subject to change. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “potentially,” “estimate,” “continue,” “expect,” “target,” similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control, and are not guarantees of future results. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the Company’s ability to obtain capital when desired on favorable terms, if at all; (ii) the Company’s ability to realize the benefits of its operational restructuring; (iii) the impact of various global conflicts on the Company’s business and general economic conditions; (iv) the Company’s ability to implement its business strategy; (v) the risk that disruptions from the operational restructuring will harm the Company’s business, including current plans and operations; (vi) the ability of the Company to retain and hire key personnel; (vii) legislative, regulatory and economic developments affecting the Company’s business; (viii) general economic and market developments and conditions; (ix) the evolving legal, regulatory and tax regimes under which the Company operates; (x) potential business uncertainty, including changes to existing business relationships that could affect the Company’s financial performance; (xi) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities; (xii) current supply chain challenges; (xiii) the financial strength of our customers and retailers; (xiv) the impact of any applicable tariffs on goods imported into the United States; (xv) competition; and (xvi) the results and impact of the Board’s strategic review of alternatives for the business, as well as the Company’s response to any of the aforementioned factors. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in the Company’s most recent annual and quarterly reports filed with the SEC and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed from time to time and available at www.sec.gov. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, or liquidity. The forward-looking statements included herein are made only as of the date hereof. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

iRobot Corporation

Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

For the three months ended

March 29, 2025

March 30, 2024

Revenue

$          101,569

$          150,014

Cost of revenue:

Cost of product revenue

79,598

113,913

Restructuring and other

1,658

Total cost of revenue

81,256

113,913

Gross profit

20,313

36,101

Operating expenses:

Research and development

14,686

33,878

Selling and marketing

26,051

29,716

General and administrative

19,016

(53,711)

Restructuring and other

6,174

14,146

Amortization of acquired intangible assets

136

172

Total operating expenses

66,063

24,201

Operating (loss) income

(45,750)

11,900

Other expense, net

(41,066)

(3,185)

(Loss) income before income taxes

(86,816)

8,715

Income tax expense

457

108

Net (loss) income

$          (87,273)

$              8,607

Net (loss) income per share:

Basic

$              (2.84)

$                0.31

Diluted

$              (2.84)

$                0.30

Number of shares used in per share calculations:

Basic

30,725

28,171

Diluted

30,725

28,266

Stock-based compensation included in above figures:

Cost of revenue

346

828

Research and development

910

2,897

Selling and marketing

965

1,338

General and administrative

3,093

2,885

Total

$              5,314

$              7,948

 

 iRobot Corporation

 Condensed Consolidated Balance Sheets

 (unaudited, in thousands)

March 29, 2025

December 28, 2024

 Assets

 Cash and cash equivalents

$            69,922

$                134,303

 Restricted cash

40,003

1,259

 Accounts receivable, net

30,804

49,865

 Inventory

68,968

76,029

 Other current assets

24,588

27,046

Total current assets

234,285

288,502

 Property and equipment, net

12,106

15,835

 Operating lease right-of-use assets

13,675

14,322

 Deferred tax assets

9,980

9,817

 Goodwill

171,548

167,288

 Intangible assets, net

3,225

3,212

 Other assets

16,690

17,161

Total assets

$          461,509

$                516,137

 Liabilities and stockholders’ (deficit) equity

 Accounts payable

$            97,298

$                106,367

 Accrued expenses

96,761

100,597

 Deferred revenue and customer advances

9,794

11,280

 Term loan

224,084

Total current liabilities

427,937

218,244

 Term loan

200,604

 Operating lease liabilities

20,348

21,598

 Other long-term liabilities

14,017

14,452

Total long-term liabilities

34,365

236,654

Total liabilities

462,302

454,898

 Stockholders’ (deficit) equity

(793)

61,239

Total liabilities and stockholders’ (deficit)
equity

$          461,509

$                516,137

 

 iRobot Corporation

Consolidated Statements of Cash Flows

 (unaudited, in thousands)

For the three months ended

March 29, 2025

March 30, 2024

Cash flows from operating activities:

Net (loss) income

$          (87,273)

$              8,607

Adjustments to reconcile net (loss) income to net cash used in operating activities:

Depreciation and amortization

2,623

5,812

Loss on equity investment

375

Stock-based compensation

5,314

7,948

Provision for inventory excess and obsolescence

384

200

Change in fair value of term loan

25,965

(1,008)

Debt issuance costs expensed under fair value option

11,614

239

Deferred income taxes, net

292

(127)

Other

1,638

(3,452)

Changes in operating assets and liabilities — (use) source

Accounts receivable

20,156

38,565

Inventory

7,434

16,066

Other assets

3,135

6,045

Accounts payable 

(9,642)

(74,601)

Accrued expenses and other liabilities

(8,100)

(3,232)

Net cash (used in) provided by operating activities

(26,460)

1,437

Cash flows from investing activities:

Additions of property and equipment

(118)

Purchase of investments

(8)

Net cash used in investing activities

(8)

(118)

Cash flows from financing activities:

Income tax withholding payment associated with restricted stock vesting

(84)

(390)

Proceeds from issuance of common stock, net of issuance costs

5,632

Repayment of term loan

(34,947)

Payment of debt issuance costs

(239)

Net cash used in financing activities

(84)

(29,944)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

922

882

Net decrease in cash, cash equivalents and restricted cash

(25,630)

(27,743)

Cash, cash equivalents and restricted cash, at beginning of period

137,951

187,887

Cash, cash equivalents and restricted cash, at end of period

$          112,321

$          160,144

Cash, cash equivalents and restricted cash, at end of period:

Cash and cash equivalents

$            69,922

$          118,356

Restricted cash

40,003

40,012

Restricted cash, non-current (included in other assets)

2,396

1,776

Cash, cash equivalents and restricted cash, at end of period

$          112,321

$          160,144

 

 iRobot Corporation

Supplemental Information

(unaudited)

For the three months ended

March 29, 2025

March 30, 2024

Revenue by Geographical Region *

United States

$            41,440

$            68,896

EMEA

32,947

45,088

Japan

21,949

27,718

Other

5,233

8,312

Total

$          101,569

$          150,014

Robot Units Shipped *

    Solo and other

98

267

    2-in-1

312

189

Total

410

456

Revenue by Product Category **

    Solo and other

$                   36

$                   94

    2-in-1

66

56

Total

$                 102

$                 150

Average gross selling prices for robot units

$                 296

$                 346

Headcount

530

1,058

* in thousands

** in millions

Certain numbers may not total due to rounding

iRobot Corporation
Explanation of Non-GAAP Measures

In addition to disclosing financial results in accordance with U.S. GAAP, this earnings release contains references to the non-GAAP financial measures described below. We use non-GAAP measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures.

Our non-GAAP financial measures reflect adjustments based on the following items. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated.

Amortization of Acquired Intangible Assets: Amortization of acquired intangible assets consists of amortization of intangible assets including completed technology, customer relationships, and reacquired distribution rights acquired in connection with business combinations as well as any non-cash impairment charges associated with intangible assets in connection with our past acquisitions. Amortization charges for our acquisition-related intangible assets are inconsistent in size and are significantly impacted by the timing and valuation of our acquisitions. We exclude these charges from our non-GAAP measures to facilitate an evaluation of our current operating performance and comparisons to our past operating performance.

Net Merger, Acquisition and Divestiture (Income) Expense: Net merger, acquisition and divestiture (income) expense primarily consists of transaction fees, professional fees, and transition and integration costs directly associated with mergers, acquisitions and divestitures, including with respect to the iRobot-Amazon Merger. It also includes business combination adjustments including adjustments after the measurement period has ended. During the first quarter of fiscal 2024, the adjustment included the one-time net termination fee received as a result of the termination of the iRobot-Amazon Merger. The occurrence and amount of these costs will vary depending on the timing and size of these transactions. We exclude these charges from our non-GAAP measures to facilitate an evaluation of our current operating performance and comparisons to our past operating performance.

Stock-Based Compensation: Stock-based compensation is a non-cash charge relating to stock-based awards. We exclude this expense as it is a non-cash expense, and we assess our internal operations excluding this expense and believe it facilitates comparisons to the performance of other companies.

Restructuring and Other: Restructuring charges are related to one-time actions associated with realigning resources, enhancing operational productivity and efficiency, or improving our cost structure in support of our strategy. Such actions are not reflective of ongoing operations and include costs primarily associated with severance and related costs, charges related to paused work unrelated to our core business, costs associated with the Chief Executive Officer transition and other non-recurring costs directly associated with resource realignments tied to strategic initiatives or changes in business conditions. We exclude these items from our non-GAAP measures when evaluating our recent and prospective business performance as such items vary significantly based on the magnitude of the action and do not reflect anticipated future operating costs. In addition, these charges do not necessarily provide meaningful insight into the fundamentals of current or past operations of our business.

Gain/Loss on Strategic Investments: Gain/loss on strategic investments includes fair value adjustments, realized gains and losses on the sales of these investments and losses on the impairment of these investments. We exclude these items from our non-GAAP measures because we do not believe they correlate to the performance of our core business and may vary in size based on market conditions and events. We believe that the exclusion of these gains or losses provides investors with a supplemental view of our operational performance.

Debt Issuance Costs: Debt issuance costs include various incremental fees paid to third parties and warrants issued in connection with the issuance or amendment of debt. We exclude these charges from our non-GAAP measures to facilitate an evaluation of our current operating performance and comparisons to our past operating performance.

Income Tax Adjustments: Income tax adjustments include the tax effect of the non-GAAP adjustments, calculated using the appropriate statutory tax rate for each adjustment. We regularly assess the need to record valuation allowances based on the non-GAAP profitability and other factors. We also exclude certain tax items, including the impact from stock-based compensation windfalls/shortfalls, which are not reflective of income tax expense incurred as a result of current period earnings. We believe disclosure of the income tax provision before the effect of such tax items is important to permit investors’ consistent earnings comparison between periods.

iRobot Corporation

Supplemental Reconciliation of GAAP Actuals to Non-GAAP Actuals

(in thousands, except per share amounts)

(unaudited)

For the three months ended

March 29, 2025

March 30, 2024

 GAAP Revenue

$          101,569

$          150,014

 GAAP Gross Profit

$            20,313

$            36,101

Stock-based compensation

346

828

Restructuring and other

1,658

 Non-GAAP Gross Profit

$            22,317

$            36,929

 GAAP Gross Margin

20.0 %

24.1 %

 Non-GAAP Gross Margin

22.0 %

24.6 %

 GAAP Operating Expenses

$            66,063

$            24,201

Amortization of acquired intangible assets

(136)

(172)

Stock-based compensation 

(4,968)

(7,120)

Net merger, acquisition and divestiture (expense) income

(949)

74,117

Restructuring and other

(6,174)

(14,146)

 Non-GAAP Operating Expenses

$            53,836

$            76,880

 GAAP Operating Expenses as a % of GAAP Revenue

65.0 %

16.1 %

 Non-GAAP Operating Expenses as a % of Non-GAAP Revenue

53.0 %

51.2 %

 GAAP Operating (Loss) Income

$          (45,750)

$            11,900

Amortization of acquired intangible assets

136

172

Stock-based compensation

5,314

7,948

Net merger, acquisition and divestiture expense (income)

949

(74,117)

Restructuring and other

7,832

14,146

 Non-GAAP Operating Loss

$          (31,519)

$          (39,951)

 GAAP Operating Margin

(45.0) %

7.9 %

 Non-GAAP Operating Margin

(31.0) %

(26.6) %

 

iRobot Corporation

Supplemental Reconciliation of GAAP Actuals to Non-GAAP Actuals continued

(in thousands, except per share amounts)

(unaudited)

For the three months ended

March 29, 2025

March 30, 2024

 GAAP Income Tax Expense

$                 457

$                 108

Tax effect of non-GAAP adjustments

48

601

Other tax adjustments

(131)

(192)

 Non-GAAP Income Tax Expense

$                 374

$                 517

 GAAP Net (Loss) Income

$          (87,273)

$              8,607

Amortization of acquired intangible assets

136

172

Stock-based compensation

5,314

7,948

Net merger, acquisition and divestiture expense (income)

949

(74,117)

Restructuring and other

7,832

14,146

Loss on strategic investments

375

Debt issuance costs

13,009

239

Income tax effect

83

(409)

 Non-GAAP Net Loss

$          (59,950)

$          (43,039)

 GAAP Net (Loss) Income Per Diluted Share

$              (2.84)

$                0.30

Amortization of acquired intangible assets

0.01

0.01

Stock-based compensation

0.17

0.28

Net merger, acquisition and divestiture expense (income)

0.03

(2.63)

Restructuring and other

0.26

0.50

Loss on strategic investments

0.01

Debt issuance costs

0.42

0.01

Income tax effect

(0.01)

 Non-GAAP Net Loss Per Diluted Share

$              (1.95)

$              (1.53)

Number of shares used in diluted per share calculation

30,725

28,171

Supplemental Information

Days sales outstanding

28

24

GAAP Days in inventory

77

107

Non-GAAP Days in inventory(1)

79

108

(1) Non-GAAP Days in inventory is calculated as inventory divided by (Revenue minus Non-GAAP Gross Profit), multiplied by 91 days.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/irobot-reports-first-quarter-2025-financial-results-302447738.html

SOURCE iRobot Corporation

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

Published

on

By

BEIJING, April 23, 2026 /PRNewswire/ — Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu’s management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of “Baidu Inc. Q1 2026 Earnings Conference Call”. Please follow the steps to enter your registration details, then click “Register”. Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10054331-iu876y.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com.

A replay of the conference call may be accessed by phone at the following number until May 25, 2026:
US: 1 855 883 1031
Reply PIN: 10054331

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and the HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

View original content:https://www.prnewswire.com/news-releases/baidu-to-report-first-quarter-2026-financial-results-on-may-18-2026-302751204.html

SOURCE Baidu, Inc.

Continue Reading

Technology

Phase 1 of 139th Canton Fair Introduces New Dedicated Product Zones as Emerging Technologies Take Center Stage

Published

on

By

GUANGZHOU, China, April 23, 2026 /PRNewswire/ — The 139th China Import and Export Fair (Canton Fair) has further optimized its exhibition landscape with nine new dedicated product zones, reflecting ongoing structural shifts in global trade and the continued upgrading of China’s export portfolio.

Among the most closely watched additions in Phase 1 are the consumer and agricultural drone zones, both making their debut at the Canton Fair and offering a focused showcase of applications in the low‑altitude economy. The consumer drone zone showcases progress in flight control, AI‑based obstacle avoidance and energy efficiency across imaging, tourism, emergency response and patrol. The agricultural drone zone highlights precision farming, with spraying, seeding and field‑management demonstrations showing terrain‑following, intelligent route planning, and precise payload control.

On day one, a Shandong‑based drone manufacturer welcomed buyers from 30+ countries, with over 50 strong leads. One buyer, after seeing load and wind‑resistance demonstrations, immediately confirmed three sample units and even proposed becoming a regional distributor.

Display technology is another focal point of Phase 1, highlighting advances in color accuracy, energy efficiency, and overall visual performance. Developments in fine‑grained control, expanded color gamut, and reduced power consumption point to a clear trend toward immersive viewing experiences combined with sustainability gains.

The smart wearables zone underscores how intelligent devices are becoming key interfaces for human‑machine interaction. From real‑time language translation and adaptive noise cancellation to long‑term health monitoring and AI‑enabled eyewear, wearables are evolving from standalone products into integrated systems that support communication, well‑being, and productivity across daily and professional settings.

The service robots zone further illustrates how artificial intelligence is moving from conceptual exploration to large‑scale deployment. Advanced robots showcased across industrial, commercial, medical, and public‑service scenarios demonstrate growing autonomy, multi‑sensory perception, and closer human-robot collaboration.

By bringing emerging technologies into clearer focus through dedicated zones, the 139th Canton Fair is reinforcing its function as a platform where trade trends take shape, innovation meets application, and global buyers gain early insights into cutting-edge technologies.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Photo – https://mma.prnewswire.com/media/2963958/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/phase-1-of-139th-canton-fair-introduces-new-dedicated-product-zones-as-emerging-technologies-take-center-stage-302751520.html

Continue Reading

Technology

OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D

Published

on

By

By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a faster, clearer way to make high-stakes R&D decisions

SPRING LAKE HEIGHTS, N.J., April 23, 2026 /PRNewswire/ — OZMOSI, a leading provider of structured pharmaceutical development intelligence, today announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

By integrating OZMOSI’s machine-readable clinical datasets directly into Planview’s AI-driven portfolio planning platform, external scientific data is now connected to internal R&D planning in one system,  helping pharmaceutical organizations better predict market shifts, prioritize R&D investments, and make faster, more confident decisions.

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what’s actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview’s platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

Together, these capabilities give teams a clearer, more complete view of the R&D landscape, grounded in clean, standardized data and strengthened by AI-driven analysis.

“AI is only as powerful as the data that fuels it,” said Beau Bush, President and Founder of OZMOSI. “Pharmaceutical organizations have no shortage of data, but too often it’s fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI’s structured data foundation together with Planview’s AI-driven planning capabilities, we’re enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making.”

“Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI,” said  Louise Allen, Chief Product Officer at Planview. “Integrating OZMOSI’s clinical intelligence into Planview’s platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning

OZMOSI’s dataset spans more than 800,000 clinical trials, over 35,000 drugs, and 4,000 diseases and conditions. It brings together insights from clinical trial registries, regulatory filings, scientific literature, company disclosures, and industry announcements into a unified, structured dataset.

When integrated into Planview’s platform, this intelligence enables pharmaceutical and biotech organizations to evaluate competitive landscapes, identify emerging clinical trends, and simulate portfolio outcomes with unprecedented precision.

Together, OZMOSI and Planview are redefining how pharmaceutical organizations approach R&D strategy, ensuring that investment decisions are guided by accurate, standardized, and AI-ready data. By combining internal portfolio visibility with a continuously updated external view of the market, the partnership helps leaders not only understand what they have, but what to do next.

About OZMOSI

Founded in 2013, OZMOSI specializes in transforming complex pharmaceutical R&D intelligence into structured, machine-readable data. The company provides the foundation needed for accurate competitive analysis, product forecasting, and portfolio strategy. Through its proprietary taxonomy and semantic layer, OZMOSI connects fragmented data across the pharmaceutical ecosystem, enabling faster, more confident decision-making for global pharma, biotech, and investment teams.

Based in Spring Lake Heights, New Jersey, OZMOSI is focused on making pharmaceutical intelligence clear, usable, and ready for the future of AI-driven strategy. Learn more at www.ozmosi.com.

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ozmosi-announces-strategic-partnership-with-planview-to-advance-ai-driven-planning-in-pharmaceutical-rd-302750944.html

SOURCE Ozmosi Company

Continue Reading

Trending